A compound traditional Chinese medicine composition for treating ulcerative colitis and its preparation method and preparation

Abstract

The invention relates to the field of medicines, in particular to a traditional Chinese medicine compound composition for treating ulcerative colitis, as well as a preparation method and a preparation of the traditional Chinese medicine compound composition. The traditional Chinese medicine compound composition comprises the following components: 6-30 parts of Chinese pulsatilla root, 6-30 parts of purslane, 6-30 parts of fried coptis chinensis, 6-30 parts of lonicera japonica charcoal, 6-30 parts of prepared rhubarb charcoal and 6-30 parts of pomegranate rind. The traditional Chinese medicine compound composition can be utilized for effectively treating experimental ulcerative colitis, mitigating the damage to colonic villi and glands, reducing the infiltration of inflammatory cells, and lowering the expression of inflammatory cell factors. The traditional Chinese medicine compound composition provided by the invention is suitable for patients with the following clinical symptoms: dysentery with pus and blood, pain of abdominal cavity and burning pain in anus, as well as heating and thirst, even irritability, reddened tongue with yellow fur, and slippery and rapid pulse.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a traditional Chinese medicine compound composition for treating ulcerative colitis, a preparation method and a preparation thereof. Background technique [0002] Ulcerative colitis (UC) is a chronic nonspecific inflammation of the colon. The lesions are mainly located in the colonic mucosa. The main clinical manifestations are abdominal pain, diarrhea, pus and blood in the stool, and tenesmus. Because the etiology of this disease is unknown, it is difficult to cure, the recurrence rate is high, and the canceration rate is high. It is one of the important refractory diseases of the digestive system. The incidence rate in the United States can reach 263 / 100,000, while it is relatively low in my country. In recent years, the number of cases of ulcerative colitis reported in my country has increased significantly. Based on the statistics of cases in many hospitals, the prevalence rate is l1...

AI Technical Summary

Problems solved by technology

Aminosalicylic acid preparations, glucocorticoids and immunosuppressants are still the main drugs for clinical treatment, but they have disadvantages such as large adverse reactions and unsatisfactory long-term efficacy

The molecular mechanism of the intestinal mucosal immune system and its progress in the pathogenesis of ulcerative colitis provide a new immunotherapy strategy for the treatment of the disease, such as targeting various cytokines, cell adhesion molecules, nuclear factor-kappaB and other pathways, But at present, only infliximab has been approved by the US FDA for the treatment of refractory ulcerative colitis, but at the same time, possible adverse reactions and relatively expensive costs restrict its application to a certain extent

Images